Lenalidomide (Revlimid™), adriamycin and dexamethasone chemotherapy (RAD) is safe and effective in treatment of relapsed multiple myeloma -: First results of a german multicenter phase I/II trial.

被引：0
|
作者：
Knop, Stefan
Gerecke, Christian
Topp, Max S.
Liebisch, Peter
Hess, Georg
Kotkiewitz, Sandra
Einsele, Hermann
Bargou, Ralf
机构：
[1] Univ Hosp, Wurzburg, Germany
[2] Charite Univ Med Berlin, Berlin, Germany
[3] Univ Hosp, Ulm, Germany
[4] Univ Hosp, Mainz, Germany
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
408
引用
收藏
页码：125A / 125A
页数：1
相关论文
共 50 条
  • [31] Combination of Lenalidomide, Melphalan, Prednisone and Thalidomide (RMPT) in Relapsed/Refractory Multiple Myeloma: Results of a Multicenter Phase II Clinical Trial
    Palumbo, Antonio
    Falco, Patrizia
    Sanpaolo, Grazia
    Falcone, Antonietta
    Ferderico, Vincenzo
    Canepa, Letizia
    Crugnola, Monica
    Baldini, Luca
    Larocca, Alessandra
    Magarotto, Valeria
    Petrucci, Maria Teresa
    Boccadoro, Mario
    BLOOD, 2008, 112 (11) : 321 - 321
  • [32] Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/II Trial
    Richardson, Paul G.
    Wolf, Jeff
    Jakubowiak, Andrzej
    Zonder, Jeff
    Lonial, Sagar
    Irwin, David
    Densmore, John
    Krishnan, Amrita
    Raje, Noopur
    Bar, Michael
    Martin, Tom
    Schlossman, Robert
    Ghobrial, Irene M.
    Munshi, Nikhil
    Laubach, Jacob
    Allerton, Jeff
    Hideshima, Teru
    Colson, Kathleen
    Poradosu, Enrique
    Gardner, Lesa
    Sportelli, Peter
    Anderson, Kenneth C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (32) : 4243 - 4249
  • [33] Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial
    Siegel, David S.
    Schiller, Gary J.
    Samaras, Christy J.
    Sebag, Michael
    Berdeja, Jesus G.
    Ganguly, Siddhartha
    Matous, Jeffrey V.
    Song, Kevin W.
    Seet, Christopher S.
    Acosta-Rivera, Mirelis
    Bar, Michael
    Quick, Donald P.
    Anz, Bertrand M., III
    Fonseca, Gustavo A.
    Reece, Donna E.
    Lee, Kim
    Chung, Weiyuan
    Agarwal, Amit
    Bahlis, Nizar J.
    BLOOD, 2020, 136
  • [34] Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma (MM): Final results of a multicenter phase I/II study
    Anderson, K. C.
    Weller, E.
    Lonial, S.
    Jakubowiak, A. J.
    Jagannath, S.
    Raje, N. S.
    Avigan, D.
    Knight, R. D.
    Esseltine, D.
    Richardson, P. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [35] RMPT in Relapsed/Refractory Multiple Myeloma: Results of a Multicenter Phase II Clinical Trial
    Palumbo, A.
    Larocca, A.
    Sanpaolo, G.
    Falcone, A. P.
    Federico, V.
    Canepa, L.
    Crugnola, M.
    Baldini, L.
    Magarotto, V.
    Falco, P.
    Petrucci, M. T.
    Boccadoro, M.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S14 - S15
  • [36] Clinical efficacy of lenalidomide {Revlimid®} in patients with relapsed or refractory chronic lymphocytic leukemia (CLL):: Updated results of a phase II clinical trial.
    Chanan-Khan, Asher Alban
    Miller, Kena C.
    Musial, Laurie
    Padmanabhan, Swaminathan
    Lawrence, David
    Bernstein, Zale P.
    Takeshita, Kenichi
    Spaner, David
    Byrne, Catriona
    Chrystal, Cynthia
    Czuczman, Myron S.
    BLOOD, 2006, 108 (11) : 95A - 95A
  • [37] A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
    Schroeder, Mark A.
    Fiala, Mark A.
    Huselton, Eric
    Cardone, Michael H.
    Jaeger, Savina
    Jean, Sae Rin
    Shea, Kathryn
    Ghobadi, Armin
    Wildes, Tanya
    Stocked-Goldstein, Keith E.
    Vij, Ravi
    CLINICAL CANCER RESEARCH, 2019, 25 (13) : 3776 - 3783
  • [38] Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial
    Palumbo, Antonio
    Larocca, Alessandra
    Genuardi, Mariella
    Kotwica, Katarzyna
    Gay, Francesca
    Rossi, Davide
    Benevolo, Giulia
    Magarotto, Valeria
    Cavallo, Federica
    Bringhen, Sara
    Rus, Cecilia
    Masini, Luciano
    Iacobelli, Massimo
    Gaidano, Gianluca
    Mitsiades, Constantine
    Anderson, Kenneth
    Boccadoro, Mario
    Richardson, Paul
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (07): : 1144 - 1149
  • [39] Final Phase I Results of Perifosine In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed or Refractory Multiple Myeloma (MM)
    Jakubowiak, Andrzej J.
    Richardson, Paul G.
    Zimmerman, Todd M.
    Alsina, Melissa
    Kaufman, Jonathan L.
    Kandarpa, Malathi
    Harvey, Colleen K.
    Colson, Kathleen
    Mitchell, Monica
    Hideshima, Teru
    Sportelli, Peter
    Gardner, Lesa
    Giusti, Kathy
    Anderson, Kenneth C.
    BLOOD, 2010, 116 (21) : 1264 - 1264
  • [40] Dasatinib in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: Preliminary Results of a Phase I Study
    Facon, Thierry
    Leleu, Xavier
    Stewart, A. Keith
    Spencer, Andrew
    Rowlings, Philip
    Hulin, Cyrille
    Attal, Michel
    Garzon, Felix
    Bleickardt, Eric
    Gialelis, Konstantina
    Tuozzoli, Doreen
    Derreumaux, Dorninique
    Sonneveld, Pieter
    BLOOD, 2009, 114 (22) : 744 - 745
12345